Dr. Kris M. Mahadeo
Claim this profileM D Anderson Cancer Center
Studies Tumors
Studies Neuroblastoma
10 reported clinical trials
29 drugs studied
Area of expertise
1Tumors
HLA-A positive
HLA positive
RB1 positive
2Neuroblastoma
HLA-A positive
HLA positive
RB1 positive
Affiliated Hospitals
Clinical Trials Kris M. Mahadeo is currently running
Non-TBI Conditioning
for HCT in Acute Lymphoblastic Leukemia
This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hematopoietic cell transplant (HCT). Patients diagnosed with B-ALL who are candidates for HCT will be screened by NGS-MRD on a test of bone marrow done before the HCT. Subjects who are pre-HCT NGS-MRD negative will be eligible to receive a non-TBI conditioning regimen as part of the treatment cohort of the study. Subjects who are pre-HCT NGS-MRD positive will be treated as per treating center standard and will be followed in an observational cohort (HCT center standard of care).
Recruiting1 award Phase 2
Stem Cell Transplant Conditioning
for SCID
The investigators want to study if lower doses of chemotherapy will help babies with SCID to achieve good immunity with less short and long-term risks of complications after transplantation. This trial identifies babies with types of immune deficiencies that are most likely to succeed with this approach and offers them transplant early in life before they get severe infections or later if their infections are under control. It includes only patients receiving unrelated or mismatched related donor transplants. The study will test if patients receiving transplant using either a low dose busulfan or a medium dose busulfan will have immune recovery of both T and B cells, measured by the ability to respond to immunizations after transplant. The exact regimen depends on the subtype of SCID the patient has. Donors used for transplant must be unrelated or half-matched related (haploidentical) donors, and peripheral blood stem cells must be used. To minimize the chance of graft-versus-host disease (GVHD), the stem cells will have most, but not all, of the T cells removed, using a newer, experimental approach of a well-established technology. Once the stem cell transplant is completed, patients will be followed for 3 years. Approximately 9-18 months after the transplant, vaccinations will be administered, and a blood test measuring whether your child's body has responded to the vaccine will be collected.
Recruiting1 award Phase 244 criteria
More about Kris M. Mahadeo
Clinical Trial Related1 year of experience running clinical trials · Led 10 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Kris M. Mahadeo has experience with
- Fludarabine Phosphate
- Tacrolimus
- Mycophenolate Mofetil
- Fludarabine
- Busulfan
- Cyclophosphamide
Breakdown of trials Kris M. Mahadeo has run
Tumors
Neuroblastoma
Nerve Sheath Tumors
Neurofibrosarcoma
Peripheral Nerve Sheath Tumor
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Kris M. Mahadeo specialize in?
Kris M. Mahadeo focuses on Tumors and Neuroblastoma. In particular, much of their work with Tumors has involved HLA-A positive patients, or patients who are HLA positive.
Is Kris M. Mahadeo currently recruiting for clinical trials?
Yes, Kris M. Mahadeo is currently recruiting for 5 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Kris M. Mahadeo has studied deeply?
Yes, Kris M. Mahadeo has studied treatments such as Fludarabine Phosphate, Tacrolimus, Mycophenolate Mofetil.
What is the best way to schedule an appointment with Kris M. Mahadeo?
Apply for one of the trials that Kris M. Mahadeo is conducting.
What is the office address of Kris M. Mahadeo?
The office of Kris M. Mahadeo is located at: M D Anderson Cancer Center, Houston, Texas 77030 United States. This is the address for their practice at the M D Anderson Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.